Cardiac Toxicity in Medical Treatment of Breast Cancer (CaTOB)

Odense University Hospital

Status

Completed

Conditions

Breast Cancer

Heart Failure

Study type

Observational

Funder types

Other

Identifiers

NCT02440620

S-20140090

Details and patient eligibility

About

This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer.

In a prospective study Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients scheduled for trastuzumab treatment at Odense University Hospital, will be offered advanced echocardiographic examination, test of bio-markers and genetic markers for the purpose of investigating if early identification of patients in particular risk of developing heart failure is feasible.

Enrollment

45 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria